Anno 2011

swipe-left
 TitoloAutoriRivista
1Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial. Galetta D, Pisconti S, Cinieri S, Pappagallo GL, Gebbia V, Borsellino N, Maiello E, Rinaldi A, Montrone M, Rizzo P, Marzano N, Sasso N, Febbraro A, Colucci G.Clin Lung Cancer. 2011 Nov;12(6):402-6. doi: 10.1016/j.cllc.2011.06.006. Epub 2011 Aug 10. PMID: 21831718.
2A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study. Vici P, Colucci G, Giotta F, Sergi D, Filippelli G, Perri P, Botti C, Vizza E, Carpino A, Pizzuti L, Latorre A, Giannarelli D, Lopez M, Di Lauro L.J Exp Clin Cancer Res. 2011 Apr 12;30(1):39. doi: 10.1186/1756-9966-30-39. PMID: 21481280; PMCID: PMC3082232.
3Cisplatin, fotemustine and whole-brain radiotherapy in non-small cell lung cancer patients with asymptomatic brain metastases: a multicenter phase II study of the Gruppo Oncologico Italia Meridionale (GOIM 2603). Galetta D, Gebbia V, Silvestris N, Ferraù F, Carrozza F, Cigolari S, Russo P, Calista F, Adamo V, Colucci G.Lung Cancer. 2011 Apr;72(1):59-63. doi: 10.1016/j.lungcan.2010.07.013. Epub 2010 Aug 21. PMID: 20728237.

L'area riservata ai soci GOIM sarà presto disponibile